First Time Loading...
I

Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 69.44 USD -1.28% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

ITCI Price Targets Summary
Intra-Cellular Therapies Inc

Wall Street analysts forecast ITCI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ITCI is 93.74 USD with a low forecast of 65.65 USD and a high forecast of 126 USD.

ITCI Lowest Forecast
Wall Street Target
65.65 USD
5% Downside
ITCI Average Forecast
Wall Street Target
93.74 USD
35% Upside
ITCI Highest Forecast
Wall Street Target
126 USD
81% Upside
Lowest
Price Target
65.65 USD
5% Downside
Average
Price Target
93.74 USD
35% Upside
Highest
Price Target
126 USD
81% Upside

ITCI Last Price Targets
Intra-Cellular Therapies Inc

The latest public price target was made on Apr 23, 2024 by Sumant Kulkarni from Canaccord Genuity , who expects ITCI stock to rise by 54% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Sumant Kulkarni
Canaccord Genuity
107 USD
Upside 54%
1 week ago
Apr 23, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
StreetInsider
Joel Beatty
Robert W. Baird
103 USD
Upside 48%
2 weeks ago
Apr 17, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $103 at Baird
StreetInsider
Ami Fadia
Needham
82 USD
Upside 18%
4 weeks ago
Apr 5, 2024
Needham remains positive on Intra-Cellular ahead of Caplyta readouts
TheFly
Sumant Kulkarni
Canaccord Genuity
Price Target 107 USD
Upside/Downside 54%
View Source
Joel Beatty
Robert W. Baird
Price Target 103 USD
Upside/Downside 48%
View Source
Ami Fadia
Needham
Price Target 82 USD
Upside/Downside 18%
View Source
Intra-Cellular Therapies Inc Competitors:
Price Targets
CARA
Cara Therapeutics Inc
550% Upside
600216
Zhejiang Medicine Co Ltd
40% Upside
C
060590
CTC Bio Inc
212% Upside
063160
CKD Bio Corp
13% Upside
CARA
Cara Therapeutics Inc
550% Upside
600216
Zhejiang Medicine Co Ltd
40% Upside
C
060590
CTC Bio Inc
212% Upside
063160
CKD Bio Corp
13% Upside
G
GRIN
Grown Rogue International Inc
29% Downside
008930
Hanmi Science Co Ltd
3% Downside
A
002821
Asymchem Laboratories Tianjin Co Ltd
34% Upside
I
300049
Inner Mongolia Furui Medical Science Co Ltd
51% Downside

Revenue
Forecast

Revenue Estimate
Intra-Cellular Therapies Inc

For the last 8 years the compound annual growth rate for Intra-Cellular Therapies Inc's revenue is 187%. The projected CAGR for the next 3 years is 42%.

187%
Past Growth
42%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Intra-Cellular Therapies Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Intra-Cellular Therapies Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
What are analyst estimates?

See Also

Summary
ITCI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ITCI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ITCI stock valuation using valuation multiples.
Wall Street Estimates
ITCI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ITCI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ITCI's stock price target?
Price Target
93.74 USD

According to Wall Street analysts, the average 1-year price target for ITCI is 93.74 USD with a low forecast of 65.65 USD and a high forecast of 126 USD.

What is Intra-Cellular Therapies Inc's Revenue forecast?
Projected CAGR
42%

For the last 8 years the compound annual growth rate for Intra-Cellular Therapies Inc's revenue is 187%. The projected CAGR for the next 3 years is 42%.

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.